Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
2006 1
2012 2
2014 1
2017 1
2018 15
2019 26
2020 33
2021 46
2022 64
2023 51
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Imel EA, et al. Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16. Lancet. 2019. PMID: 31104833 Free PMC article. Clinical Trial.
Eligible patients were randomly assigned (1:1) to receive either subcutaneous burosumab starting at 0.8 mg/kg every 2 weeks (burosumab group) or conventional therapy prescribed by investigators (conventional therapy group). ...Treatment-emergent adverse events consi …
Eligible patients were randomly assigned (1:1) to receive either subcutaneous burosumab starting at 0.8 mg/kg every 2 weeks (buros …
An Overview of Rickets in Children.
Chanchlani R, Nemer P, Sinha R, Nemer L, Krishnappa V, Sochett E, Safadi F, Raina R. Chanchlani R, et al. Kidney Int Rep. 2020 Apr 11;5(7):980-990. doi: 10.1016/j.ekir.2020.03.025. eCollection 2020 Jul. Kidney Int Rep. 2020. PMID: 32647755 Free PMC article. Review.
There are other subtypes of rickets, such as vitamin D-dependent type 1 rickets and vitamin D-dependent type 2 rickets (due to defects in vitamin D metabolism), renal rickets (due to poor kidney function), and hypophosphatemic rickets (vitamin D-resistant rickets secondary to ren …
There are other subtypes of rickets, such as vitamin D-dependent type 1 rickets and vitamin D-dependent type 2 rickets (due to defects in vi …
Approach to Hypophosphatemic Rickets.
Ackah SA, Imel EA. Ackah SA, et al. J Clin Endocrinol Metab. 2022 Dec 17;108(1):209-220. doi: 10.1210/clinem/dgac488. J Clin Endocrinol Metab. 2022. PMID: 35981346 Free PMC article.
The treatment depends on the underlying cause, but often includes active forms of vitamin D combined with phosphate salts, or anti-FGF23 antibody treatment (burosumab) for X-linked hypophosphatemia. The purpose of this article is to explore the approach to evaluating hypop …
The treatment depends on the underlying cause, but often includes active forms of vitamin D combined with phosphate salts, or anti-FGF23 ant …
Tumor-induced Osteomalacia: A Comprehensive Review.
Minisola S, Fukumoto S, Xia W, Corsi A, Colangelo L, Scillitani A, Pepe J, Cipriani C, Thakker RV. Minisola S, et al. Endocr Rev. 2023 Mar 4;44(2):323-353. doi: 10.1210/endrev/bnac026. Endocr Rev. 2023. PMID: 36327295 Review.
Burosumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000040 Free Books & Documents. Review.
No information is available on the clinical use of burosumab alfa during breastfeeding. Because burosumab alfa is a large protein molecule with a molecular weight of about 170,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially …
No information is available on the clinical use of burosumab alfa during breastfeeding. Because burosumab alfa is a large prot …
Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, Kumar R, Rauch F, Luca D, Cimms T, Roberts MS, San Martin J, Carpenter TO. Jan de Beur SM, et al. J Bone Miner Res. 2021 Apr;36(4):627-635. doi: 10.1002/jbmr.4233. Epub 2021 Jan 12. J Bone Miner Res. 2021. PMID: 33338281 Free PMC article. Clinical Trial.
UX023T-CL201 is an ongoing, open-label, phase 2 study investigating the safety and efficacy of burosumab, a fully human monoclonal antibody that inhibits FGF23, in adults with TIO or cutaneous skeletal hypophosphatemia syndrome (CSHS). ...Nine patients had 16 treatment-rel …
UX023T-CL201 is an ongoing, open-label, phase 2 study investigating the safety and efficacy of burosumab, a fully human monoclonal an …
Burosumab: First Global Approval.
Lamb YN. Lamb YN. Drugs. 2018 Apr;78(6):707-714. doi: 10.1007/s40265-018-0905-7. Drugs. 2018. PMID: 29679282 Review.
In April 2018, the US FDA approved burosumab for the treatment of XLH in adults and children one year of age and older. Multinational phase III trials of burosumab are currently underway in adult and paediatric patients with XLH. ...
In April 2018, the US FDA approved burosumab for the treatment of XLH in adults and children one year of age and older. Multinational …
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S. Fukumoto S. J Mol Endocrinol. 2021 Feb;66(2):R57-R65. doi: 10.1530/JME-20-0089. J Mol Endocrinol. 2021. PMID: 33295878 Review.
Burosumab has been approved in several countries including Europe, North America and Japan. Long-term effects of burosumab need to be addressed in future studies....
Burosumab has been approved in several countries including Europe, North America and Japan. Long-term effects of burosumab nee …
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D. Haffner D, et al. Pediatr Nephrol. 2022 Oct;37(10):2289-2302. doi: 10.1007/s00467-022-05505-5. Epub 2022 Mar 29. Pediatr Nephrol. 2022. PMID: 35352187 Free PMC article.
Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts in combination with active vitamin D, whereas tumor-induced osteomalacia (TIO) should primarily undergo tumor resection, if possible. Bu …
Fibroblast-growth factor 23 (FGF23)-associated hypophosphatemic rickets was historically treated with frequent doses of oral phosphate salts …
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högler W, Simmons JH, Gottesman GS, Padidela R, Namba N, Cheong HI, Nilsson O, Mao M, Chen A, Skrinar A, Roberts MS, Imel EA. Ward LM, et al. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3241-e3253. doi: 10.1210/clinem/dgac296. J Clin Endocrinol Metab. 2022. PMID: 35533340 Free PMC article. Clinical Trial.
On burosumab, dental abscesses were not reported in younger children but were in 53% of older children. CONCLUSION: Burosumab appears to improve outcomes both in younger and older children with XLH, including rickets, lower limb deformities, growth, and ALP, compare …
On burosumab, dental abscesses were not reported in younger children but were in 53% of older children. CONCLUSION: Burosumab …
220 results